TSHA logo

Taysha Gene Therapies, Inc. (TSHA) Cash and Cash Equivalents

Annual Cash & Cash Equivalents:

$139.04M-$4.90M(-3.41%)
December 31, 2024

Summary

  • As of today, TSHA annual cash & cash equivalents is $139.04 million, with the most recent change of -$4.90 million (-3.41%) on December 31, 2024.
  • During the last 3 years, TSHA annual cash & cash equivalents has fallen by -$10.07 million (-6.75%).
  • TSHA annual cash & cash equivalents is now -44.66% below its all-time high of $251.25 million, reached on December 31, 2020.

Performance

TSHA Cash and Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTSHAbalance sheet metrics

Quarterly Cash & Cash Equivalents:

$297.79M-$15.42M(-4.92%)
September 30, 2025

Summary

  • As of today, TSHA quarterly cash & cash equivalents is $297.79 million, with the most recent change of -$15.42 million (-4.92%) on September 30, 2025.
  • Over the past year, TSHA quarterly cash & cash equivalents has increased by +$139.66 million (+88.31%).
  • TSHA quarterly cash & cash equivalents is now -4.92% below its all-time high of $313.21 million, reached on June 30, 2025.

Performance

TSHA Quarterly Cash & Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTSHAbalance sheet metrics

Cash and Cash Equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

TSHA Cash and Cash Equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1Y1 Year-3.4%+88.3%
3Y3 Years-6.8%+768.0%
5Y5 Years+100.0%+6.9%

TSHA Cash and Cash Equivalents Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs Low
3Y3-Year-6.8%+58.2%-4.9%+768.0%
5Y5-Year-44.7%>+9999.0%-4.9%+768.0%
All-TimeAll-Time-44.7%>+9999.0%-4.9%+2558.9%

TSHA Cash and Cash Equivalents History

DateAnnualQuarterly
Sep 2025
-
$297.79M(-4.9%)
Jun 2025
-
$313.21M(+167.6%)
Mar 2025
-
$117.04M(-16.1%)
Dec 2024
$139.04M(-3.4%)
$139.49M(-11.8%)
Sep 2024
-
$158.14M(-8.7%)
Jun 2024
-
$173.19M(+39.2%)
Mar 2024
-
$124.43M(-13.8%)
Dec 2023
$143.94M(+63.8%)
$144.39M(-12.1%)
Sep 2023
-
$164.28M(+264.4%)
Jun 2023
-
$45.08M(-28.9%)
Mar 2023
-
$63.42M(-27.8%)
Dec 2022
$87.88M
$87.88M(+156.2%)
DateAnnualQuarterly
Sep 2022
-
$34.31M(-48.2%)
Jun 2022
-
$66.24M(-31.5%)
Mar 2022
-
$96.63M(-35.2%)
Dec 2021
$149.10M(-40.7%)
$149.10M(-21.0%)
Sep 2021
-
$188.78M(-4.3%)
Jun 2021
-
$197.37M(-13.7%)
Mar 2021
-
$228.68M(-9.0%)
Dec 2020
$251.25M(>+9900.0%)
-
Dec 2020
-
$251.25M(-9.8%)
Sep 2020
-
$278.63M(+2387.8%)
Jun 2020
-
$11.20M
Dec 2019
$0.00
-

FAQ

  • What is Taysha Gene Therapies, Inc. annual cash & cash equivalents?
  • What is the all-time high annual cash & cash equivalents for Taysha Gene Therapies, Inc.?
  • What is Taysha Gene Therapies, Inc. annual cash & cash equivalents year-on-year change?
  • What is Taysha Gene Therapies, Inc. quarterly cash & cash equivalents?
  • What is the all-time high quarterly cash & cash equivalents for Taysha Gene Therapies, Inc.?
  • What is Taysha Gene Therapies, Inc. quarterly cash & cash equivalents year-on-year change?

What is Taysha Gene Therapies, Inc. annual cash & cash equivalents?

The current annual cash & cash equivalents of TSHA is $139.04M

What is the all-time high annual cash & cash equivalents for Taysha Gene Therapies, Inc.?

Taysha Gene Therapies, Inc. all-time high annual cash & cash equivalents is $251.25M

What is Taysha Gene Therapies, Inc. annual cash & cash equivalents year-on-year change?

Over the past year, TSHA annual cash & cash equivalents has changed by -$4.90M (-3.41%)

What is Taysha Gene Therapies, Inc. quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of TSHA is $297.79M

What is the all-time high quarterly cash & cash equivalents for Taysha Gene Therapies, Inc.?

Taysha Gene Therapies, Inc. all-time high quarterly cash & cash equivalents is $313.21M

What is Taysha Gene Therapies, Inc. quarterly cash & cash equivalents year-on-year change?

Over the past year, TSHA quarterly cash & cash equivalents has changed by +$139.66M (+88.31%)
On this page